Literature DB >> 28413579

Metabolic Recovery of the Failing Heart: Emerging Therapeutic Options.

Dale J Hamilton1.   

Abstract

Heart failure has mortality rates that parallel those of breast cancer. Current management strategies include neurohormonal blockade, rate control measures, natriuretic peptide preservation, implantation of mechanical assist devices, and heart transplantation. Despite these strategies, however, the failing myocardium remains energy depleted. New strategies to promote metabolic recovery are being developed to potentially augment current treatment guidelines. For example, an unexpected finding of our own studies showed that mechanical unloading with assist devices in advanced-stage heart failure restored metabolic flux. Unfortunately, at that point it is too late for myocardial recovery. Traditional metabolic therapies addressing hyperglycemia have had limited long-term outcome benefit. Now, new therapeutic options are emerging based on increased understanding of the molecular mechanisms underlying energy depletion. Metabolic cardiac imaging combined with laboratory diagnostics could guide the design of individual therapeutic strategies. To date, agents that show benefit in select individuals include mimetics that stimulate glucagon-like peptide-1, inhibitors of sodium-glucose cotransporter receptors, drugs that limit fatty acid oxidation, and hormonal therapy in select individuals. This review will summarize mechanisms and investigations related to these metabolic approaches to heart failure.

Entities:  

Keywords:  energy recovery; heart failure; metabolic management

Mesh:

Substances:

Year:  2017        PMID: 28413579      PMCID: PMC5385791          DOI: 10.14797/mdcj-13-1-25

Source DB:  PubMed          Journal:  Methodist Debakey Cardiovasc J        ISSN: 1947-6108


  30 in total

1.  Noninvasive Detection of Early Metabolic Left Ventricular Remodeling in Systemic Hypertension.

Authors:  Yasmin S Hamirani; Bijoy K Kundu; Min Zhong; Andrew McBride; Yinlin Li; Giovanni E Davogustto; Heinrich Taegtmeyer; Jamieson M Bourque
Journal:  Cardiology       Date:  2015-11-24       Impact factor: 1.869

2.  SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.

Authors:  Muhammad Abdul-Ghani; Stefano Del Prato; Robert Chilton; Ralph A DeFronzo
Journal:  Diabetes Care       Date:  2016-05       Impact factor: 19.112

3.  Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.

Authors:  Kiwon Ban; M Hossein Noyan-Ashraf; Judith Hoefer; Steffen-Sebastian Bolz; Daniel J Drucker; Mansoor Husain
Journal:  Circulation       Date:  2008-04-21       Impact factor: 29.690

Review 4.  Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.

Authors:  Eiji Kurosaki; Hideaki Ogasawara
Journal:  Pharmacol Ther       Date:  2013-04-04       Impact factor: 12.310

5.  Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people.

Authors:  Pardeep S Jhund; Kate Macintyre; Colin R Simpson; James D Lewsey; Simon Stewart; Adam Redpath; James W T Chalmers; Simon Capewell; John J V McMurray
Journal:  Circulation       Date:  2009-01-19       Impact factor: 29.690

6.  Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart.

Authors:  Karpagam Aravindhan; Weike Bao; Mark R Harpel; Robert N Willette; John J Lepore; Beat M Jucker
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

7.  Expression of SGLT1 in Human Hearts and Impairment of Cardiac Glucose Uptake by Phlorizin during Ischemia-Reperfusion Injury in Mice.

Authors:  Yusuke Kashiwagi; Tomohisa Nagoshi; Takuya Yoshino; Toshikazu D Tanaka; Keiichi Ito; Tohru Harada; Hiroyuki Takahashi; Masahiro Ikegami; Ryuko Anzawa; Michihiro Yoshimura
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

8.  Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.

Authors:  Leong Lee; Ross Campbell; Michaela Scheuermann-Freestone; Rachel Taylor; Prasad Gunaruwan; Lynne Williams; Houman Ashrafian; John Horowitz; Alan G Fraser; Kieran Clarke; Michael Frenneaux
Journal:  Circulation       Date:  2005-11-22       Impact factor: 29.690

9.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse
Journal:  N Engl J Med       Date:  2016-06-13       Impact factor: 176.079

10.  Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design.

Authors:  Jagdeep S S Singh; Amir Fathi; Keeran Vickneson; Ify Mordi; Mohapradeep Mohan; J Graeme Houston; Ewan R Pearson; Allan D Struthers; Chim C Lang
Journal:  Cardiovasc Diabetol       Date:  2016-07-15       Impact factor: 9.951

View more
  1 in total

Review 1.  Regulating microRNA expression: at the heart of diabetes mellitus and the mitochondrion.

Authors:  Quincy A Hathaway; Mark V Pinti; Andrya J Durr; Shanawar Waris; Danielle L Shepherd; John M Hollander
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-10-06       Impact factor: 4.733

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.